Topic resource collection
Approved comparison material connected to this topic.
7 resourcesRead both sides
Cerebrolysin BDNF/NGF mimetic. TrkB receptor activation Passive diffusion (400–800 Da peptides) 2.5–5 mL/kg body weight Refrigerate at 2–8°C; 28-day post-reconstitution window Most extensively studied neuropeptide. 200+ trials in…
Cerebrolysin Multi-peptide neurotrophic factor mimetic. Promotes synaptogenesis and reduces excitotoxicity 6 RCTs in vascular dementia (Cochrane 2019). Modest ADAS-cog improvement, high bias risk 10–30mL IV infusion, 5 days/week,…
Before selecting a peptide, understand which memory pathway is impaired. Cholinergic deficiency presents differently than neurotrophic insufficiency or mitochondrial dysfunction. And the compounds that address each are mechanisti…
The evidence base for peptide-based memory enhancement spans three tiers: in vitro receptor binding studies, animal behavioural models, and human clinical trials. Most compounds marketed as cognitive enhancers never progress beyo…
Semax BDNF upregulation via melanocortin receptor binding Human RCTs in healthy adults 600mcg intranasal 2× daily, 14–28 days Intranasal (olfactory pathway) Strongest evidence for near-term memory retention improvement in cogniti…
Dihexa HGF mimetic; c-Met receptor activation → synaptogenesis 0.1–2 mg/kg (subcutaneous or oral) Oral: 50–60%; Subcutaneous: ~100% 28 days at 2–8°C Highest potency-per-dose; oral administration viable; limited human safety data …
Before selecting a peptide for memory research, understanding the comparative profiles across mechanism, dosing, timeline, and application context is essential. The table below distills clinical and preclinical evidence for the m…